Personalized stent treatment.

…

• is an early-stage medical device start-up.• develops a breakthrough remote and in situ monitoring

technology (patent pending) that can equip all stents turning theminto connected healthcare devices.

• is protected from competitors by patents and a unique know-how.• aims to save 1 patient every 15 min.• is driven by a multi-disciplinary team.• is supported by world class scientific, medical and business

advisors.• offers a 2 B€ opportunity in an innovation-driven market.• is laureate of the World Innovation Competition, the i-LAB

competition, the Hello Tomorrow Challenge, the JLGerondeau/Zodiac Aerospace Prize and Tremplin Entreprises.

• is seeking 1.4M€ (0.4M€ remain) seed funding to go to first-in-animal.

2

3

Stents are designed to prevent heart attacks

Blood-thinner

4

Limited information: 1 death/15 min

Blood clot in stent

Stent in artery

50 % survival rate

5

How long should the blood-thinner treatment last?

More than 12 months? Less than 6 months?

Stent thrombosis has only a 50% survival rate!

High risk patient population > 25%

Major bleeding has an increased mortality risk!

High risk patient population > 15%

Mauri – “Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents”, N Engl J Med 2014

6

Doctors explicitly express their need

2013The optimum duration of DAPT after coronary stenting isunknown and depends on individual patient and proceduralcriteria. The PARIS registry shows a pronouncedheterogeneity of treatment patterns and risk in patients whodiscontinue DAPT. …

… Importantly, a one-size-fits-all approach to guide DAPTduration is likely to oversimplify what is a rather more complexclinical decision. …

CURRENT ATHEROSCLEROSIS REPORTSSep 2015

More than 30 articles in 2015 alone (PubMed)

7

Instent monitors healing process in situ

8

First smart stent prototype in action

9

Two successful animal trials in 2015

10

Instent’s sensor characterizes the stent’s in situ environment: key to monitoring healing

smooth-muscle cells

blood clot

no cellsendothelial cells

11

Smart stent data benefits all stakeholders and leads to a safer and more cost-efficient treatment

• Increased market share• Reduced development cost

• Optimized pooling of patient risk• Increased efficiency of the

healthcare system

• Online stent implantation procedure feedback

• Improved understanding of disease pathology

• Tailored & preventive treatment

• Accompanied life-style changes• Better compliance due to a better

understanding of the disease

12

Stent market expected to reach 8 billion €

Annual growth rate

Market breakdown 2014Sources: “Coronary Stents - Global Trends, Estimates and Forecasts, 2012-2018,” Axis Research Mind, 2014

“Global Coronary Stents Market (Drug Eluting & Bare Metal) Is Expected To Reach USD 8.3 Billion By 2016,” Transparency Market Research, 2013

%↑9%

↑3%

↑10%

13

Innovators own the market

Bare metal stents

Sources: Leerink & assumption of stable BMS market since 2004

1st generationdrug-eluting stents

2nd generationdrug-eluting stents

J&J Cordis

Boston Scientific

Abbott

Other0%

10%

20%

30%

40%

50%

60%

1999 2001 2003 2005 2007 2009 2011 2013 2015 2017

Medtronic

US

ste

nt

ma

rket

sh

are

*

14

… and experienced business mentors

Franz Bozsak, PhDCEO & co-founder

Stent technology expertStanford Ignite Graduate

Abdul Barakat, PhDCSA & co-founder

Biomechanics & atherosclerosis expertAXA Chair holder

Bruno CarreelR&D manager & CTO

Micro-electronics expert

Pierluca Messina, PhDR&D manager

Sensor expert

Myline Cottance, PhDR&D manager

Manufacturing expert

Florian Reinaud, MDMedical entrepreneur

Sacha Loiseau, PhDCEO & founder, Mauna Kea Technologies

Eric Le RoyerMedTech entrepreneur& Industry expert

Yvan Bonnassieux, PhDEcole polytechnique

Pioneer in organic electronics

Bruno Le Pioufle, PhDENS Cachan

Expert in biosensors

Antoine Lafont, MD, PhDHôpital européenGeorges-Pompidou,co-founder ART

Top 5 interventional cardiologist in France

Ulrich Sigwart, MD, PhDemer. University of Geneva

Pioneer of vascular stenting

Gonzague IssenmannMedTech entrepreneur & Industry expert

Gor Lebedev, PhDR&D manager

Analysis & simulation expert

Nathalie Bufi, PhDOperations manager

15

Q3 ’19EU market

entry

Q4 ’17First-in-human

Q4 ’16First-in-animal

Instent’s milestones to market

16

The stent is only the beginning

17

A breakthrough technology (patent pending) aligned with current and future trends in healthcare (connected health,

big data, reduced healthcare costs).

A well-networked team with world-class scientific, medical and business advisors.

A 2 B€ opportunity in an innovation-driven market.

Prototyping phase under way in best-in-class environment at Ecole polytechnique.

Company is seeking seed money to leverage significant non-dilutive funding from various sources.

www.instent.eu | contact@instent.eu | Follow us on /instent_